Lexaria rises after cannabis-based formulation shows promising results in study
08/12/2021 13:35
** U.S.-listed shares of Canadian drug delivery platforms
maker, Lexaria Bioscience Corp LEXX.O up ~29% at $6.37
premarket, its highest in nearly a month
** Says positive follow-up data from clinical study of
investigational candidate - DehydraTECHTM-processed cannabidiol
(CBD) - indicates potential to broaden its indications
urn:newsml:reuters.com:*:nTnwc5rRLr
** DehydraTECH is a drug delivery technology developed by co
and cannabidiol is an active ingredient found in the cannabis
plant
** Data shows DehydraTECH-CBD reduces arterial stiffness,
potentially broadening its application to treatment of
cardiovascular and other diseases beyond hypertension where it
has already shown tremendous promise- LEXX
** Co says significant blood pressure reduction effects
previously reported with DehydraTECH-CBD, appear to have been at
least partially due to these improvements in arterial stiffness
** Up to Tuesday's close, stock had fallen 34.22% YTD
(Reporting by Oishee Majumdar in Bengaluru)
((oishee.majumdar@thomsonreuters.com;))